Gene · 8405
Papers2,215
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 2,215
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Thinking (Metastasis) outside the (Primary Tumor) Box. | Cancers (Basel) | 2023 | 38001575 | PubTator, text mining | PubMed |
| Wnt Signaling and Therapeutic Resistance in Castration-Resistant Prostate Cancer. | Curr Pharmacol Rep | 2023 | 37994344 | PubTator, text mining | PubMed |
| A novel intronic circular RNA circFGFR1int2 up-regulates FGFR1 by recruiting transcriptional activators P65/FUS and suppressing miR-4687-5p to promote prostate cancer progression. | J Transl Med | 2023 | 37993879 | PubTator, text mining | PubMed |
| Differential Impact of SPOP Mutation in Prostate and Endometrial Cancers. | JCO Precis Oncol | 2023 | 37972335 | PubTator, text mining | PubMed |
| Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cancer therapy. | Acta Pharm Sin B | 2023 | 37969742 | PubTator, text mining | PubMed |
| Liquid-liquid phase separation in DNA double-strand breaks repair. | Cell Death Dis | 2023 | 37968256 | PubTator, text mining | PubMed |
| Unveiling the Molecular Landscape of FOXA1 Mutant Prostate Cancer: Insights and Prospects for Targeted Therapeutic Strategies. | Int J Mol Sci | 2023 | 37958805 | PubTator, text mining | PubMed |
| Biomarkers for Prostate Cancer: From Diagnosis to Treatment. | Diagnostics (Basel) | 2023 | 37958246 | PubTator, text mining | PubMed |
| A pathway activity-based proteomic classifier stratifies prostate tumors into two subtypes. | Clin Proteomics | 2023 | 37950160 | PubTator, text mining | PubMed |
| Retracted: SPOP Inhibition of Endometrial Carcinoma and Its Clinicopathological Relationship. | Appl Bionics Biomech | 2023 | 37946808 | PubTator, text mining | PubMed |
| SPOP regulates the expression profiles and alternative splicing events in human hepatocytes. | Open Life Sci | 2023 | 37941785 | PubTator, text mining | PubMed |
| Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy. | Ann Med | 2023 | 37939258 | PubTator, text mining | PubMed |
| Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance. | J Transl Med | 2023 | 37936202 | PubTator, text mining | PubMed |
| Ablation of the GDP-fucose transporter suppresses lung cancer cell proliferation and migration by reducing expression of PD-L1. | J Cancer | 2023 | 37928424 | PubTator, text mining | PubMed |
| Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. | Signal Transduct Target Ther | 2023 | 37926722 | PubTator, text mining | PubMed |
| Reduction of oligomer size modulates the competition between cluster formation and phase separation of the tumor suppressor SPOP. | J Biol Chem | 2023 | 37926283 | PubTator, text mining | PubMed |
| Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer. | J Transl Med | 2023 | 37925432 | PubTator, text mining | PubMed |
| Inflammation-related signature for prognostic prediction, tumor immune, genomic heterogeneity, and drug choices in prostate cancer: Integrated analysis of bulk and single-cell RNA-sequencing. | Heliyon | 2023 | 37920511 | PubTator, text mining | PubMed |
| BCLAF1-induced HIF-1α accumulation under normoxia enhances PD-L1 treatment resistances via BCLAF1-CUL3 complex. | Cancer Immunol Immunother | 2023 | 37906282 | PubTator, text mining | PubMed |
| Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis. | Cell Commun Signal | 2023 | 37904149 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8405/papers?page=13